741871
Last Update Posted: 2012-04-20
Recruiting has ended
All Genders accepted | 18 Years + |
35 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
Eligibility
Relevant conditions:
Lymphoma, Malignant
Hodgkin's Lymphoma
B Cell Lymphoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov